Epigenetic Therapies to Enhance Checkpoint Inhibitor Efficacy in Melanoma

Why This Research Matters
Immunotherapy has dramatically improved treatment for melanoma, the most serious form of skin cancer. Drugs called immune checkpoint inhibitors can help the immune system recognize and attack cancer cells, and for some patients they produce long-lasting responses. However, about half of patients do not benefit enough from these treatments, and many tumors eventually become resistant. One major reason is that the cancer-fighting immune cells, called CD8 T cells, become “exhausted.” When this happens, they lose their ability to effectively kill tumor cells.

What We Are Studying
Our research focuses on understanding why these T cells become exhausted and whether that process can be reversed. We are especially interested in DNA methylation, a chemical marking system that acts like a set of instructions telling cells which genes to turn on or off. In exhausted T cells, these instructions may lock the cells into a weak, dysfunctional state, even when immunotherapy is given. We believe that changing these instructions could help restore T cells to a healthier, more powerful state.

How the Study Works
This project has two main goals. First, we will identify the specific enzymes and DNA sites that drive T cell exhaustion in melanoma. Second, we will test whether drugs that change DNA methylation can make immunotherapy work better. We will do this in mouse models of melanoma and in tumor-infiltrating immune cells from patients with melanoma.

Expected Impact
This research is innovative because it shifts the focus of DNA methylation therapy away from cancer cells themselves and toward the immune cells fighting the cancer. If successful, this work could lead to new treatment strategies that improve immunotherapy responses for patients with melanoma who currently do not benefit from existing therapies.